Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

David Adams, Alejandra González‐Duarte, William O’Riordan, Chih‐Chao Yang, Mitsuharu Ueda, Arnt V. Kristen, Ivailo Tournev, Hartmut Schmidt, Teresa Coelho, John L. Berk, Kon-Ping Lin, Giuseppe Vita, Shahram Attarian, Violaine Planté‐Bordeneuve, Michelle M. Mezei, Josep M. Campistol, Juan Buades, Thomas H. Brannagan, Byoung J. Kim, Jeeyoung Oh, Yeşim Parman, Yoshiki Sekijima, Philip N. Hawkins, Scott D. Solomon, Michael Polydefkis, P. James B. Dyck, Pritesh J. Gandhi, Sunita Goyal, Jihong Chen, Andrew Strahs, Saraswathy V. Nochur, Marianne T. Sweetser, Pushkal Garg, Akshay Vaishnaw, Jared Gollob, Ole B. Suhr

New England Journal of Medicine, 2018

Inserm, Université Paris-Sud, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, National Taiwan University Hospital, Heidelberg University, National Institute of Emergency Medicine "Pirogov", Klinik für Schlafmedizin, University Hospital Münster, Hospital de Santo António, Centro Hospitalar do Porto, Boston Medical Center, Amyloidosis Foundation, Taipei Veterans General Hospital, University of Messina, Hôpital de la Timone, Centre Hospitalier Universitaire Henri-Mondor, Vancouver General Hospital, Hospital Clínic de Barcelona, Health Research Institute of the Balearic Islands, Hospital Son Llatzer, Columbia University, Samsung Medical Center, Sungkyunkwan University, Konkuk University Medical Center, Istanbul University, Shih Hsin University, University College London, Harvard University, Johns Hopkins University, Johns Hopkins Bayview Medical Center, Mayo Clinic in Arizona, Alnylam Pharmaceuticals (United States), Umeå University

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

2856

Citations

View on Google Scholar

Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis

Abstract

Journal Details

Join JournalsHub

Welcome Back